apitegromab tirzepatide Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with During Tirzepatide-Induced Weight Loss Apitegromab, a selective antimyostatin monoclonal
Pay in 4 interest-free payments of $6.45 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4



























